Albireo to Participate in the Needham 20th Annual Virtual Healthcare Conference
06 April 2021 - 02:30PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver
disease company developing novel bile acid modulators, today
announced participation in the upcoming Needham 20th Annual
Healthcare Conference on April 12-15. Albireo executives taking
part will include Ron Cooper, President and Chief Executive Officer
and Simon Harford, Chief Financial Officer. The team will
participate in a fireside chat on April 13 at 9:30 a.m. ET, which
will be available on-demand on the Albireo Media & Investors
page at ir.albireopharma.com, as well as hosting meeting with
investors throughout the conference.
About Albireo
Albireo Pharma is a clinical-stage
biopharmaceutical company focused on the development of novel bile
acid modulators to treat rare pediatric and adult liver diseases.
Albireo’s lead product candidate, odevixibat, is being developed to
treat rare pediatric cholestatic liver diseases with Phase 3 trials
in PFIC, Alagille syndrome and biliary atresia. The Company has
initiated a Phase 1 clinical trial for A3907 to advance development
in adult cholestatic liver disease, with IND-enabling studies
moving ahead with A2342 for viral and cholestatic liver disease.
Albireo was spun out from AstraZeneca in 2008 and is headquartered
in Boston, Massachusetts, with its key operating subsidiary in
Gothenburg, Sweden. The Boston Business Journal named Albireo one
of the 2020 Best Places to Work in Massachusetts for the second
consecutive year. For more information on Albireo, please visit
www.albireopharma.com.
Media & Investor
Contacts:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comHans
Vitzthum, LifeSci Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2023 bis Mär 2024